Bridging the Needs of Security and Development Teams, Veracode Unveils Next-Generation Software Security Platform
Veracode, a leading global provider of application security testing (AST) solutions, today announced its Continuous Software Security Platform, which seamlessly embeds application security into the software development lifecycle (SDLC). The platform streamlines workflows by bringing together development and security teams to provide a broad understanding of risk, remediation guidance, and progress at every stage of the development process.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220504005671/en/
Fig. 1 The Veracode Continuous Software Security Platform (Graphic: Business Wire)
According to Veracode’s latest research, there has been a 20x increase in average scan cadence over the past decade, with most applications tested three times per week, as opposed to three times per year a decade ago. The research also showed a 31 percent increase in organizations using multiple scan types over the last three years alone.
Today, leading organizations recognize the need to leverage multiple methods to assess their software and do so across all stages of the development lifecycle. Gartner® predicts that “by 2025, 70% of organizations will consolidate the number of vendors securing the lifecycle of cloud-native applications to a maximum of three vendors.” ¹ This suggests companies are already looking for a comprehensive platform that provides flexible policy management, a holistic assessment of software risk, and integrated remediation guidance, while simplifying the complexity of managing multiple solutions.
Pervasive but Not Invasive for Developers
With increased pressure to build and deploy software at breakneck speed, development teams require security checks to be seamlessly integrated into the tools where they work so they can find and fix vulnerabilities quickly. Meanwhile, security teams must meet increasingly stringent compliance standards defined by their boards and regulatory bodies. Veracode’s Continuous Software Security Platform is pervasive but not invasive because it provides a frictionless experience for developers by embedding vulnerability analysis with remediation guidance directly into the integrated development environment.
Brian Roche, Chief Product Officer at Veracode, said, “Other vendors in our space have incomplete or disjointed solutions that lack consistent reporting and analysis, leaving customers playing a game of ‘whack a mole’ across different tools. We have continued to evolve our platform to create a seamless and integrated experience for developers, as well as provide security teams with a holistic view of their software security posture from design, through development and deployment. We see this as a win for both development and security teams that will result in the delivery of software that is more secure.”
Veracode Continuous Software Security Platform
The Veracode Continuous Software Security Platform enables users to define and manage security policy, gain a comprehensive view of software security across their application portfolio, and leverage rich analytics to make informed plans, communicate metrics, comply with policy, and meet regulatory requirements. Powered by almost two decades of data, the platform enables organizations to detect, predict, manage, and, ultimately, mitigate their security risk. These intelligent capabilities empower companies to deliver secure code at the speed and scale expected in today’s world.
The new Veracode Continuous Software Security Platform release features several new capabilities including:
- Single-Pane-of-Glass Reporting: Security teams can now access unified reporting directly in the portal for Static Analysis, Dynamic Analysis, Software Composition Analysis, and Manual Penetration Testing. Administrators and developers now have a consolidated view into security risks, as well as flexible policy controls through stronger license management reports to address issues quickly.
- Self-Service Peer Benchmarking: With comprehensive data and anonymized insights across all platform users, customers now have direct access to reports on the portal, which enable them to easily benchmark their DevSecOps program results against others in their industry. Tapping into many years of data and learning, customers can see how their program metrics stack up and establish plans to address their risk.
- Software Bill of Materials (SBOM): Security teams can now generate and export SBOMs on demand with an integrated representational state transfer (REST) API. This returns data for a specific application in CycloneDX SBOM format—a standard designed for use in application security contexts and supply chain component analysis. Additionally, data from the API can be mined and transformed outside of the Veracode Platform.
- Intelligent Remediation: The Continuous Software Security Platform will leverage technology acquired from Jaroona to detect and remediate software vulnerabilities through machine learning. Jaroona, which was recognized by Gartner Research as a “Cool Vendor” in 2021, outperforms traditional approaches by 7x to 10x in terms of accuracy, false negatives, and false positive rates, and reduces the burden on technical resources.
According to Tabrez Naqvi, Director of Information Security and Risk at Cox Automotive, “The security of our products and services is very important to us, and Veracode helps us ensure that we never lose our customers' trust and confidence."
For more information on the Veracode Continuous Software Security Platform visit https://www.veracode.com/platform.
¹Gartner, Inc. ”Predicts 2022: Consolidated Security Platforms Are the Future” by Charlie Winckless, Joerg Fritsch, Peter Firstbrook, Neil MacDonald, Brian Lowans, 1 December 2021
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.
About Veracode
Veracode is a leading AppSec partner for creating secure software, reducing the risk of security breach, and increasing security and development teams’ productivity. As a result, companies using Veracode can move their business, and the world, forward. With its combination of process automation, integrations, speed, and responsiveness, Veracode helps companies get accurate and reliable results to focus their efforts on fixing, not just finding, potential vulnerabilities.
Learn more at www.veracode.com, on the Veracode blog and on Twitter.
Copyright © 2022 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220504005671/en/
Contact information
For more information, please contact:
Katy Gwilliam
kgwilliam@veracode.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
A-CAP Announces Successful Divestiture of Standard de Liège SA and Immobilière du Standard de Liège SRL6.6.2025 23:32:00 EEST | Press release
Advantage Capital Holdings, LLC (“A-CAP” or “The Company”), a New York-based insurance and financial services company with over $12 billion in assets, today announced the successful divestiture of Standard de Liège SA (“Standard Liège” or the “Club”), one of Belgium's most historic soccer clubs, and Immobilière du Standard de Liège SRL, the corporate entity that owns the Club's stadium, Maurice Dufrasne Stadium, to a consortium of buyers led by Standard Liège Chief Executive Officer Giacomo Angelini. This transaction marks the end of 777 Partners’ legacy involvement with the Club and sets the stage for the Club’s future growth and success, both on and off the field. Benefits of the transaction include: Increased stability across the Club’s shareholder base, which clears the path for future investments, Operational clarity, establishing a unified direction that will allow both players and management to fully concentrate on on-field performance, ensuring that collective focus remains on
Populous Acquires Fentress Architects, Expanding Global Aviation Portfolio6.6.2025 21:00:00 EEST | Press release
Populous, the world-renowned design firm specializing in sport and entertainment venues, today announced the acquisition of Denver-based Fentress Architects, a global leader in iconic aviation projects and prominent public buildings, including convention centers, museums and government facilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606849000/en/ Los Angeles International Airport. Designed by Fentress Architects. This strategic acquisition unites two of the most respected names in architecture, combining Populous’ unparalleled expertise in designing memorable experiences with Fentress’ award-winning portfolio of aviation, civic and cultural landmarks. The acquisition significantly broadens the scope and scale of services that Populous can offer clients across the globe. Bruce Miller, Populous Global Chair and CEO, commented: “We are committed to expanding the breadth of our practice. Fentress Architects has lon
Vertex Presents New Data on Benefits of ALYFTREK ® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 19:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conference, the Company presented data from a pooled analysis across CFTR modulators, including ALYFTREK, which demonstrate that reduction in sweat chloride (SwCl), and therefore greater restoration of CFTR function, is associated with improved outcomes in people with cystic fibrosis (CF). For all clinical outcomes in the study, SwCl levels below 60 mmol/L were associated with greater benefit
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10 th Anniversary Year of NAHYCO ® Technology6.6.2025 17:00:00 EEST | Press release
IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the latest innovations and cutting-edge advancements in aesthetic procedures and treatments, staying at the forefront of this dynamic field. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603094257/en/ IBSA’s stand at IMCAS Asia 2025 As part of the congress, IBSA Derma will host a scientific symposium titled “The Future of Tissue Regeneration with NAHYCO® Technology. Feeling and Seeing the Results with Profhilo® Line” scheduled for Saturday, June 7, from 3:00 to 4:00 pm ICT in Room 1 - Level 2. Internationally renowned speakers – Dr. Lam Bee Lan and Prof. Ofir Artzi – will lead
HistoSonics Completes Enrollment in #HOPE4KIDNEY Trial Evaluating Non-Invasive Histotripsy to Treat Kidney Tumors6.6.2025 15:00:00 EEST | Press release
HistoSonics, Inc., the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the completion of patient enrollment in its pivotal #HOPE4KIDNEY trial. This prospective, multi-center, single-arm trial is designed to evaluate the safety and effectiveness of the Edison System in destroying kidney tissue by treating primary solid kidney tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606659747/en/ Edison Histotripsy System Procedure for Kidney Tumor Animation The trial enrolled patients with a single, non-metastatic solid kidney mass ≤3 cm, confirmed by imaging and biopsy. Subjects will be followed for five years post-procedure, with evaluations at multiple time points, including 14-day, 30-day, 90-day, 180-day, and annual assessments. The Edison System remains in investigational use for kidney applications and is not yet FDA-approved for this indication. Data from the #H
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom